How Genetics Influence GLP-1 Weight Loss and Diabetes Drug Effectiveness

New research published in the journal Nature on April 8, 2026, has identified genetic variants that influence how individuals respond to GLP-1 receptor agonist medications. These drugs, which include semaglutide (marketed as Wegovy and Ozempic) and tirzepatide (marketed as Zepbound and Mounjaro), have become central to the clinical management of obesity and overweight conditions, though their efficacy varies significantly between patients.

The study, conducted by the 23andMe Research Institute, analyzed self-reported data from 27,885 people who had undergone GLP-1 receptor agonist therapy. The goal was to investigate the genetic basis for the substantial inter-person variability observed in both weight loss outcomes and the incidence of treatment-related side effects.

Genetic Predictors of Weight Loss

Researchers identified a specific missense variant in the GLP1R gene, which encodes the receptor that these medications activate to increase satiety. This variant, identified as rs10305420, is significantly associated with increased weight loss efficacy.

According to the findings, each copy of the effect allele is expected to result in an additional 0.76 kg of weight loss. The data shows that individuals with one copy of this variant lost an average of approximately 1.7 pounds more than those without it, while those with two copies of the variant lost more than three pounds more than individuals with no copies.

Adam Auton, a study co-author and vice president of human genetics at the 23andMe Research Institute, stated that the result makes perfect biological sense because the variant is located directly within the gene for the GLP-1 receptor, which is the target for these medications.

Impact on Side Effects and Resistance

Beyond weight loss, the study examined the genetic drivers of common side effects. The researchers found associations linking variation in both the GLP1R and GIPR genes to the occurrence of nausea or vomiting related to GLP-1 medication.

Notably, the association involving the GIPR gene was restricted to patients using tirzepatide. These findings suggest that genetic screening could eventually be used to stratify patients based on their risk for side effects and their likely efficacy of treatment.

Separate reports indicate that genetic factors may also contribute to drug resistance. Some data suggests that approximately one in 10 people may exhibit resistance to GLP-1 diabetes drugs, and nearly one in four people using these weight-loss medications may not respond to treatment, losing little to no weight and seeing few health improvements.

Precision Medicine and Limitations

The identification of these variants provides direct genetic evidence that variation in drug target genes contributes to how different people respond to GLP-1 therapies. This research lays the foundation for precision medicine approaches in obesity treatment, potentially allowing clinicians to predict which patients will benefit most from specific medications.

However, scientists caution that these common gene variants do not fully explain the variability in weight loss. While the identified variants provide clues, they cannot account for all the reasons why some individuals lose significantly more weight than others during treatment.

• The study utilized a genome-wide association study (GWAS) of nearly 28,000 participants.
• The GLP1R variant rs10305420 is linked to higher efficacy in weight loss.
• GIPR variations are specifically linked to nausea and vomiting in tirzepatide users.
• Genetic markers may help identify the subset of the population that is resistant to these medications.